The biologics license application for afamitresgene autoleucel, an engineered T-cell receptor drug, was assigned a PDUFA date of August 4, 2024.
FDA Grants Priority Review to Adaptimmune's T-Cell Therapy for Advanced Synovial Sarcoma
Posted on by admin
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
1 min read
+ There are no comments
Add yours